Related Experiment Videos
[Human papillomavirus testing in cervical cancer screening]
Mathias K Fehr1, Stéphane Welti
1Klinik für Gynäkologie, Departement Frauenheilkunde, Universitätsspital Zürich, Zürich, Schweiz. Mathias.Fehr@usz.ch
Gynakologisch-Geburtshilfliche Rundschau
|June 24, 2004
Summary
Human papillomavirus (HPV) testing is valuable for screening cervical cancer precursors in specific populations. Its high negative predictive value aids in managing screening intervals and identifying patients needing immediate treatment.
Area of Science:
- Gynecologic Oncology
- Virology
- Public Health
Context:
- Cervical cancer is predominantly caused by oncogenic human papillomavirus (HPV) types.
- High HPV prevalence in young women limits routine testing value.
- Risk stratification for cervical pre-cancer depends on HPV type, duration, and viral load.
Purpose:
- To evaluate the utility of HPV testing in various clinical scenarios for cervical cancer screening and management.
- To determine the role of HPV testing in conjunction with cytology for different age groups and risk factors.
Summary:
- HPV testing combined with cytology is effective for elderly women, allowing extended screening intervals (3-5 years).
- It serves as a triage tool for atypical squamous cells of undetermined significance, especially when immediate colposcopy is deferred.
- HPV testing aids in managing post-treatment follow-up after cone biopsy and identifying high-risk patients with atypical glandular lesions or immunocompromised status.
Impact:
- Optimizes cervical cancer screening strategies by stratifying risk and guiding treatment decisions.
- Enhances patient management by enabling personalized follow-up intervals based on HPV status.
- Reduces unnecessary interventions and healthcare costs by accurately identifying low-risk individuals.